Given the increase in tumor parenchyma-infiltrating SPAS-1+ CD8+ T cells in refractory tumors following combination IRE + anti-CTLA-4 therapy, we also wondered if these tumor-specific T cells adopted characteristics of tissue-resident memory cells. The gene discussed is CTLA4; the disease is neoplasm.